White Paper: The Evolving Role of Antigen Testing in the COVID-19 Pandemic Response
The report reviews the two basic types of diagnostic tests exist for SARS-CoV-2 virus detection, for which the US Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs):
- Polymerase chain reaction (PCR) tests—also referred to as reverse transcription PCR (RT-PCR) tests—use a laboratory-based molecular approach to detect genetic material (ribonucleic acid, or RNA) from the virus in a nasal or throat swab or in saliva.
- Antigen tests, which may be performed at the point of care, detect specific proteins on or within the virus by testing a nasal swab or saliva sample.
The Pandemic Defense and Economic Recovery System
From sports stadiums, airlines, cruise ships, and concert venues to healthcare facilities, corporate campuses, and universities, to safely open to full capacity and maintain business continuity every environment requires:
- scalable technology
Latest Investor Presentation - January 14, 2020
We are developing a revolutionary Pandemic Defense and Economic Recovery System that will usher in the ‘the new normal’. It’s first testing system will be Antigen based with a throughput capacity of 2,500 tests per hour. Preliminary LOD 90x lower than the nearest competitor.
Please join Bill Phelan, CEO of FluroTest for an executive presentation on the FluroTest Pandemic Defense and Economic Recovery Platform
In the News
FluroTest and SNC-Lavalin Sign MoU to Bring Saliva Sample-Based SARS-CoV-2 Testing Solution System to Market in Canada and Beyond
FluroTest and SNC-Lavalin Sign MoU to Bring Saliva Sample-Based SARS-CoV-2 Testing Solution System to Market in Canada and Beyond CALGARY, AB and MONTRÉAL, May 13, 2021 /PRNewswire/ – FluroTech
Clinical Trial Progresses Across Six Clinical Site Locations Throughout the US CALGARY, AB, May 10, 2021 /CNW/ – FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostics Systems (“FluroTest”
FluroTest Prepares to Detect SARS-CoV-2 Variants of Concern with High-Throughput COVID-19 Testing Platform
CALGARY, AB, May 4, 2021 /CNW/ – FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) and subsidiary FluroTest Diagnostics Systems (“FluroTest” or The Company), a first-mover in surge-scale rapid antigen testing for the detection
Former US Assistant Secretary for Health, Admiral Joxel Garcia, MD, Joins Flurotest Advisory Board to Support COVID-19 Rapid Antigen Testing System for the Masses
Former US Assistant Secretary for Health, Admiral Joxel Garcia, MD, joins FluroTest advisory board to support COVID-19 rapid antigen testing system for the masses. Surging
FluroTech Shareholders to Control 100% of Pandemic Defense Testing System CALGARY, Alberta, March 15, 2021 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”),
Media & Press Inquiries
To get in touch with the Press Team at FluroTest, please fill out the contact form with your press inquiry and our team will be in touch.